IL312721A - Novel TALE protein scaffolds with improved on-target/off-target activity ratios - Google Patents

Novel TALE protein scaffolds with improved on-target/off-target activity ratios

Info

Publication number
IL312721A
IL312721A IL312721A IL31272124A IL312721A IL 312721 A IL312721 A IL 312721A IL 312721 A IL312721 A IL 312721A IL 31272124 A IL31272124 A IL 31272124A IL 312721 A IL312721 A IL 312721A
Authority
IL
Israel
Prior art keywords
target
improved
protein scaffolds
tale protein
activity ratios
Prior art date
Application number
IL312721A
Other languages
English (en)
Hebrew (he)
Original Assignee
Cellectis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis Sa filed Critical Cellectis Sa
Publication of IL312721A publication Critical patent/IL312721A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL312721A 2021-11-23 2022-11-23 Novel TALE protein scaffolds with improved on-target/off-target activity ratios IL312721A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163282453P 2021-11-23 2021-11-23
DKPA202270104 2022-03-15
PCT/EP2022/082950 WO2023094435A1 (en) 2021-11-23 2022-11-23 New tale protein scaffolds with improved on-target/off-target activity ratios

Publications (1)

Publication Number Publication Date
IL312721A true IL312721A (en) 2024-07-01

Family

ID=84487474

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312721A IL312721A (en) 2021-11-23 2022-11-23 Novel TALE protein scaffolds with improved on-target/off-target activity ratios

Country Status (9)

Country Link
US (1) US20250002945A1 (enExample)
EP (1) EP4437091A1 (enExample)
JP (1) JP2024540639A (enExample)
KR (1) KR20240110844A (enExample)
AU (1) AU2022395500A1 (enExample)
CA (1) CA3238700A1 (enExample)
IL (1) IL312721A (enExample)
MX (1) MX2024006051A (enExample)
WO (1) WO2023094435A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4583890A1 (en) * 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2025181336A1 (en) 2024-03-01 2025-09-04 Cellectis Sa Compositions and methods for hbb-editing in hspc
KR20250148471A (ko) * 2024-04-02 2025-10-14 재단법인 아산사회복지재단 핵산 결합 단백질 및 SsdA를 포함하는 융합단백질 및 이의 용도
WO2026046724A1 (en) 2024-08-30 2026-03-05 Cellectis Sa Tale protein scaffolds involving fusions of monopartite and bipartite nls

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
EP2737066B1 (en) 2011-07-29 2017-11-08 Cellectis High throughput method for assembly and cloning polynucleotides comprising highly similar polynucleotidic modules
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US10378007B2 (en) * 2012-09-03 2019-08-13 Cellectis Methods for modulating TAL specificity
CA2913872C (en) 2013-05-31 2022-01-18 Cellectis A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof

Also Published As

Publication number Publication date
EP4437091A1 (en) 2024-10-02
WO2023094435A1 (en) 2023-06-01
MX2024006051A (es) 2024-06-26
CA3238700A1 (en) 2022-11-23
US20250002945A1 (en) 2025-01-02
AU2022395500A1 (en) 2024-05-23
KR20240110844A (ko) 2024-07-16
JP2024540639A (ja) 2024-10-31

Similar Documents

Publication Publication Date Title
EP4093863A4 (en) Crispr-cas enzymes with enhanced on-target activity
DK3917394T3 (da) Analyte sensors employing multiple enzymes
EP4211234A4 (en) Base editing enzymes
SI4094804T1 (sl) Arilamidni derivat s protitumorsko aktivnostjo
EP4090739A4 (en) Single cell sequencing
EP4388083A4 (en) VASCULARIZED ORGANOIDS
EP4129662A4 (en) Biosensor
EP4426826A4 (en) BASIC EDITION ENZYMES
EP4746343A2 (en) SECURING BROWSER CONNECTION WARNINGS
EP4397100A4 (en) SMART PAGING
EP4203094A4 (en) ELECTRODE
EP4235004A4 (en) Coupling structure
EP4392561A4 (en) Enzymes with RuVC domains
EP4246139A4 (en) BIOSENSOR
EP4191699A4 (en) Electrode
EP4209666C0 (en) UREA SENSOR
EP4208484A4 (en) MODIFIED CORONAVIRUS STRUCTURAL PROTEIN
EP4117180A4 (en) CONNECTED STRUCTURE
EP4153934C0 (en) ELECTRODE SUPPORTED ON CLOTHING
EP4482953A4 (en) MODIFIED DNASE ENZYMES FOR IMPROVED STABILITY
DK3962534T3 (da) Proteiner med kardioprotektiv aktivitet
EP4204552A4 (en) Engineered amylase variants
EP4289943A4 (en) ENZYME FOR DEAMIDATION OF PROTEINS
EP4190681C0 (en) ARTICULATED STRUCTURE
EP4187239A4 (en) ELECTRODE